The fibrin-derived γ377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease

Perivascular microglia activation is a hallmark of inflammatory demyelination in multiple sclerosis (MS), but the mechanisms underlying microglia activation and specific strategies to attenuate their activation remain elusive. Here, we identify fibrinogen as a novel regulator of microglia activation and show that targeting of the interaction of fibrinogen with the microglia integrin receptor Mac-1 (αMβ2, CD11b/CD18) is sufficient to suppress experimental autoimmune encephalomyelitis in mice that retain full coagulation function. We show that fibrinogen, which is deposited perivascularly in MS plaques, signals through Mac-1 and induces the differentiation of microglia to phagocytes via activation of Akt and Rho. Genetic disruption of fibrinogen–Mac-1 interaction in fibrinogen-γ390-396A knock-in mice or pharmacologically impeding fibrinogen–Mac-1 interaction through intranasal delivery of a fibrinogen-derived inhibitory peptide (γ377-395) attenuates microglia activation and suppresses relapsing paralysis. Because blocking fibrinogen–Mac-1 interactions affects the proinflammatory but not the procoagulant properties of fibrinogen, targeting the γ377-395 fibrinogen epitope could represent a potential therapeutic strategy for MS and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation.

[1]  David H. Miller,et al.  Disease-modifying treatments in multiple sclerosis , 2006 .

[2]  Stephen R. Clark,et al.  A Requirement for Microglial TLR4 in Leukocyte Recruitment into Brain in Response to Lipopolysaccharide , 2006, The Journal of Immunology.

[3]  F. Tacke,et al.  A Novel Model of Demyelinating Encephalomyelitis Induced by Monocytes and Dendritic Cells1 , 2006, The Journal of Immunology.

[4]  H. Kessler,et al.  Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. , 2006, Current pharmaceutical design.

[5]  M. Barnett,et al.  The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion , 2006, Multiple sclerosis.

[6]  F. Barkhof,et al.  Blood–brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis , 2005, Neurobiology of Disease.

[7]  A. Bar-Or,et al.  Microglia and multiple sclerosis , 2005, Journal of neuroscience research.

[8]  F. Helmchen,et al.  Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.

[9]  L. Steinman,et al.  Multiple sclerosis: trapped in deadly glue , 2005, Nature Medicine.

[10]  S. Miller,et al.  Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis , 2005, Nature Medicine.

[11]  B. Becher,et al.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis , 2005, Nature Medicine.

[12]  B. Becher,et al.  Experimental autoimmune encephalomyelitis repressed by microglial paralysis , 2005, Nature Medicine.

[13]  Alastair Compston,et al.  McAlpine's Multiple Sclerosis , 2005 .

[14]  J. Degen,et al.  Fibrin(ogen)-αMβ2 Interactions Regulate Leukocyte Function and Innate Immunity In Vivo , 2004 .

[15]  J. Feramisco,et al.  Rho‐mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2 , 2004, Journal of neurochemistry.

[16]  W. Mandemakers,et al.  The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination , 2004, Nature Neuroscience.

[17]  Benjamin D. Sachs,et al.  Fibrin mechanisms and functions in nervous system pathology. , 2004, Molecular interventions.

[18]  R. Thorne,et al.  Intranasal administration of interferon beta bypasses the blood–brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis , 2004, Journal of Neuroimmunology.

[19]  D. Witte,et al.  Leukocyte engagement of fibrin(ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo , 2004 .

[20]  H. Lassmann,et al.  Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Akassoglou,et al.  Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  L. Björck,et al.  M Protein, a Classical Bacterial Virulence Determinant, Forms Complexes with Fibrinogen that Induce Vascular Leakage , 2004, Cell.

[23]  M. Glogauer,et al.  Cytoskeletal remodeling in leukocyte function , 2004, Current opinion in hematology.

[24]  J. Degen,et al.  Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. , 2004, Experimental biology and medicine.

[25]  C. Brosnan,et al.  Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis , 2004, Acta Neuropathologica.

[26]  Hiroki Toda,et al.  Inflammatory Blockade Restores Adult Hippocampal Neurogenesis , 2003, Science.

[27]  Alireza Minagar,et al.  Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.

[28]  S. Lord,et al.  Sequence γ377−395(P2), but Not γ190−202(P1), Is the Binding Site for the αMI-Domain of Integrin αMβ2 in the γC-Domain of Fibrinogen† , 2003 .

[29]  Pamela L. Follett,et al.  Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Siao,et al.  Cell Type-Specific Roles for Tissue Plasminogen Activator Released by Neurons or Microglia after Excitotoxic Injury , 2003, The Journal of Neuroscience.

[31]  S. Lord,et al.  Sequence gamma 377-395(P2), but not gamma 190-202(P1), is the binding site for the alpha MI-domain of integrin alpha M beta 2 in the gamma C-domain of fibrinogen. , 2003, Biochemistry.

[32]  S. Rotshenker.  Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease , 2003, Journal of Molecular Neuroscience.

[33]  S. Youssef,et al.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease , 2002, Nature.

[34]  M. Carson.  Microglia as liaisons between the immune and central nervous systems: Functional implications for multiple sclerosis , 2002, Glia.

[35]  T. Ugarova,et al.  Regulated Unmasking of the Cryptic Binding Site for Integrin αMβ2 in the γC-Domain of Fibrinogen† , 2002 .

[36]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[37]  P. Hawkins,et al.  Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. , 2002, Current opinion in cell biology.

[38]  Pamela L. Follett,et al.  The Toll-Like Receptor TLR4 Is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS , 2002, The Journal of Neuroscience.

[39]  K. Akassoglou,et al.  Fibrin Inhibits Peripheral Nerve Remyelination by Regulating Schwann Cell Differentiation , 2002, Neuron.

[40]  K. Akassoglou,et al.  Nervous System Pathology: The Fibrin Perspective , 2002, Biological chemistry.

[41]  T. Ugarova,et al.  Regulated unmasking of the cryptic binding site for integrin alpha M beta 2 in the gamma C-domain of fibrinogen. , 2002, Biochemistry.

[42]  S. Grinstein,et al.  Phagocytosis and the microtubule cytoskeleton. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[43]  H. Kiyono,et al.  Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE). , 2001, Vaccine.

[44]  T. Ugarova,et al.  Recognition of Fibrinogen by Leukocyte Integrins , 2001, Annals of the New York Academy of Sciences.

[45]  S. Rotshenker,et al.  Modulation (Inhibition and Augmentation) of Complement Receptor-3-Mediated Myelin Phagocytosis , 2001, Neurobiology of Disease.

[46]  C. Lucchinetti,et al.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.

[47]  M. Ehlers,et al.  CR3: a general purpose adhesion-recognition receptor essential for innate immunity. , 2000, Microbes and infection.

[48]  S. Vukusic,et al.  [Disease-modifying treatments in multiple sclerosis]. , 1999, La Revue du praticien.

[49]  I. Weissman,et al.  Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Guo,et al.  Nasal administration of transforming growth factor-β1 induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis , 1999, Multiple sclerosis.

[51]  S. Kaveri,et al.  Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). , 1999, Blood.

[52]  A. Hall,et al.  Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. , 1998, Science.

[53]  G. Kollias,et al.  Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. , 1998, The American journal of pathology.

[54]  T. Ugarova,et al.  Identification of a Novel Recognition Sequence for Integrin αMβ2 within the γ-chain of Fibrinogen* , 1998, The Journal of Biological Chemistry.

[55]  H. Link,et al.  Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats , 1998, Journal of Neuroimmunology.

[56]  M. Esiri,et al.  The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. , 1997, Brain : a journal of neurology.

[57]  T. Owens,et al.  Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis , 1997, Journal of Neuroimmunology.

[58]  B. Coller.  Perspectives Series: Cell Adhesion in Vascular Biology Platelet Gpiib/iiia Antagonists: the First Anti-integrin Receptor Therapeutics , 2022 .

[59]  N. Yanagisawa,et al.  Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats , 1996, Journal of Neuroimmunology.

[60]  L. Laan,et al.  Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-α and nitric oxide , 1996, Journal of Neuroimmunology.

[61]  Moses Rodriguez,et al.  Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.

[62]  J. Eaton,et al.  Molecular determinants of acute inflammatory responses to biomaterials. , 1996, The Journal of clinical investigation.

[63]  E Ruoslahti,et al.  RGD and other recognition sequences for integrins. , 1996, Annual review of cell and developmental biology.

[64]  J. Prineas,et al.  Blood‐Brain Barrier Abnormalities in Longstanding Multiple Sclerosis Lesions. An Immunohistochemical Study , 1994, Journal of neuropathology and experimental neurology.

[65]  A. Wakefield,et al.  Immunohistochemical study of vascular injury in acute multiple sclerosis. , 1994, Journal of clinical pathology.

[66]  L. Languino,et al.  Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway , 1993, Cell.

[67]  A. Cross,et al.  Central nervous system endothelial cell-polymorphonuclear cell interactions during autoimmune demyelination. , 1991, The American journal of pathology.

[68]  J. Loike,et al.  CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[69]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[70]  P. Isaacson,et al.  Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.

[71]  P. Mannucci,et al.  Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen , 1988, The Journal of cell biology.

[72]  E Ruoslahti,et al.  New perspectives in cell adhesion: RGD and integrins. , 1987, Science.

[73]  A. Laudano,et al.  Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen. , 1981, Science.

[74]  C. Brosnan,et al.  The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis. , 1981, Journal of immunology.

[75]  S. Shapiro,et al.  The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. , 1978, The Journal of laboratory and clinical medicine.

[76]  Paterson Py.  Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. , 1976, Federation proceedings.